Synceres Biosciences Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series A1

  • Investors
  • 7

Synceres Biosciences General Information

Description

Developer of synthetic biology. The company mainly uses microorganisms as cell factories. With the help of engineering science concepts, through the logical design and directional evolution of gene combination, gene regulation network and signal transduction pathway, providing clients with new functional pathways or new enzymes to produce various active ingredient products.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 402, block B, Nanshan medical device Industrial Park, No. 1019
  • Nanhai Avenue, Shekou, Nanshan District
  • Shenzhen, Guangdong
  • China
+86 177
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 402, block B, Nanshan medical device Industrial Park, No. 1019
  • Nanhai Avenue, Shekou, Nanshan District
  • Shenzhen, Guangdong
  • China
+86 177

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Synceres Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A1) 15-Jun-2023 Completed Generating Revenue
2. Early Stage VC (Series A) 16-Mar-2022 Completed Generating Revenue
1. Early Stage VC 21-Feb-2021 Completed Generating Revenue
To view Synceres Biosciences’s complete valuation and funding history, request access »

Synceres Biosciences Patents

Synceres Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025245775-A1 Separation and purification method for squalene produced by biosynthesis and fermentation Pending 30-May-2024
WO-2024197449-A1 Exogenous promoter in saccharomyces cerevisiae and use of exogenous promoter in synthetic biology Inactive 24-Mar-2023
WO-2024197447-A1 Hmg-coa reductase mutant and use thereof in production of terpenoids Inactive 24-Mar-2023
WO-2024113412-A1 Microbial cell for producing cannabigerol, construction method therefor, and use thereof Inactive 03-Dec-2022
WO-2024098353-A1 Recombinant saccharomyces cerevisiae for producing cannabigerolic acid, construction method therefor, and use thereof Inactive 11-Nov-2022
To view Synceres Biosciences’s complete patent history, request access »

Synceres Biosciences Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bloomage International Corporation Minority
Co-Stone Capital PE/Buyout Minority
New Value Capital (China) Venture Capital Minority
Shenzhen Chongshi Private Equity Investment Fund Management PE/Buyout Minority
Tasly Holding Group Corporation Minority
You’re viewing 5 of 7 investors. Get the full list »

Synceres Biosciences FAQs

  • When was Synceres Biosciences founded?

    Synceres Biosciences was founded in 2019.

  • Where is Synceres Biosciences headquartered?

    Synceres Biosciences is headquartered in Shenzhen, China.

  • What industry is Synceres Biosciences in?

    Synceres Biosciences’s primary industry is Drug Discovery.

  • Is Synceres Biosciences a private or public company?

    Synceres Biosciences is a Private company.

  • What is Synceres Biosciences’s current revenue?

    The current revenue for Synceres Biosciences is .

  • How much funding has Synceres Biosciences raised over time?

    Synceres Biosciences has raised $15.8M.

  • Who are Synceres Biosciences’s investors?

    Bloomage International, Co-Stone Capital, New Value Capital (China), Shenzhen Chongshi Private Equity Investment Fund Management, and Tasly Holding Group are 5 of 7 investors who have invested in Synceres Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process